The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? - PubMed (original) (raw)
. 2016 Sep;33(9):2239-49.
doi: 10.1007/s11095-016-1961-x. Epub 2016 Jun 7.
Affiliations
- PMID: 27271335
- DOI: 10.1007/s11095-016-1961-x
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?
Christian Lubich et al. Pharm Res. 2016 Sep.
Abstract
Purpose: Recent findings demonstrated anti-PEG antibody formation in some healthy individuals and patients who have not received PEGylated biotherapeutics. Some of these findings evoked criticism because of shortcomings in the antibody assays used. To better understand this topic, we established robust antibody analytics and screened two cohorts of healthy individuals and one cohort of hemophilia patients for the expression of anti-PEG antibodies.
Methods: A flow cytometry approach and a fully validated ELISA platform were established to detect specific anti-PEG antibodies. Immunohistochemistry was used to test for potential binding of anti-PEG antibodies to human tissues.
Results: IgM and/or IgG anti-PEG antibodies are expressed by some healthy individuals and by some patients with hemophilia who have not received PEGylated biotherapeutics. These antibodies can be either transient or persistent and recognize PEGs of different sizes with or without terminal methoxy groups. Age and location of healthy individuals influence the prevalence of IgG but not of IgM antibodies. Anti-PEG antibodies do not cross-react with human tissues supporting the safety of the antibodies.
Conclusion: We confirm that some healthy individuals and some patients with hemophilia express specific antibodies against PEG which are not associated with any pathology and do not bind to human tissues.
Keywords: PEGylated proteins; anti-PEG antibodies in healthy individuals; anti-PEG antibodies in hemophilia patients; human tissue cross-reactivity study; specificity of anti-PEG antibodies.
Similar articles
- Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals.
Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, Cheng TL, Chen YT, Wu JY, Roffler SR. Chen BM, et al. Anal Chem. 2016 Nov 1;88(21):10661-10666. doi: 10.1021/acs.analchem.6b03109. Epub 2016 Oct 21. Anal Chem. 2016. PMID: 27726379 - Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population.
Yang Q, Jacobs TM, McCallen JD, Moore DT, Huckaby JT, Edelstein JN, Lai SK. Yang Q, et al. Anal Chem. 2016 Dec 6;88(23):11804-11812. doi: 10.1021/acs.analchem.6b03437. Epub 2016 Nov 16. Anal Chem. 2016. PMID: 27804292 Free PMC article. - Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice.
Chang TC, Chen BM, Wu JY, Cheng TL, Roffler S. Chang TC, et al. Biomed Pharmacother. 2022 Feb;146:112502. doi: 10.1016/j.biopha.2021.112502. Epub 2021 Dec 7. Biomed Pharmacother. 2022. PMID: 34891120 - Antibodies against polyethylene glycol in human blood: A literature review.
Hong L, Wang Z, Wei X, Shi J, Li C. Hong L, et al. J Pharmacol Toxicol Methods. 2020 Mar-Apr;102:106678. doi: 10.1016/j.vascn.2020.106678. Epub 2020 Jan 23. J Pharmacol Toxicol Methods. 2020. PMID: 31981619 Review. - Anti-polyethyleneglycol antibody response to PEGylated substances.
Ishida T, Kiwada H. Ishida T, et al. Biol Pharm Bull. 2013;36(6):889-91. doi: 10.1248/bpb.b13-00107. Biol Pharm Bull. 2013. PMID: 23727911 Review.
Cited by
- Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.
Lee CS, Kulkarni Y, Pierre V, Maski M, Wanner C. Lee CS, et al. BioDrugs. 2024 Nov;38(6):795-819. doi: 10.1007/s40259-024-00684-z. Epub 2024 Oct 17. BioDrugs. 2024. PMID: 39417964 Free PMC article. Review. - Immunofilaments Are Well Tolerated after Local or Systemic Administration in Mice.
Weiss L, Classens R, Schluck M, Grad E, Dölen Y, van der Woude L, van Midden D, Maassen L, Verrijp K, van Riessen K, van Dinther E, Hagemann PM, Figdor CG, Hammink R. Weiss L, et al. ACS Pharmacol Transl Sci. 2024 May 3;7(6):1874-1883. doi: 10.1021/acsptsci.4c00180. eCollection 2024 Jun 14. ACS Pharmacol Transl Sci. 2024. PMID: 38898947 - Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment.
Zhang S, Zhang X, Gao H, Zhang X, Sun L, Huang Y, Zhang J, Ding B. Zhang S, et al. Pharmaceutics. 2024 Apr 12;16(4):531. doi: 10.3390/pharmaceutics16040531. Pharmaceutics. 2024. PMID: 38675192 Free PMC article. Review. - Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol.
Bento C, Katz M, Santos MMM, Afonso CAM. Bento C, et al. Org Process Res Dev. 2024 Apr 1;28(4):860-890. doi: 10.1021/acs.oprd.3c00428. eCollection 2024 Apr 19. Org Process Res Dev. 2024. PMID: 38660381 Free PMC article. Review. - Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering.
Isaac AH, Recalde Phillips SY, Ruben E, Estes M, Rajavel V, Baig T, Paleti C, Landsgaard K, Lee RH, Guda T, Criscitiello MF, Gregory C, Alge DL. Isaac AH, et al. Nat Commun. 2024 Apr 18;15(1):3283. doi: 10.1038/s41467-024-46327-3. Nat Commun. 2024. PMID: 38637507 Free PMC article.
References
- Rheumatology (Oxford). 2002 Oct;41(10):1133-7 - PubMed
- Drug Discov Today. 2014 Dec;19(12 ):1945-52 - PubMed
- Arthritis Res Ther. 2006;8(1):R12 - PubMed
- Thromb Haemost. 2015 Jan;113(1):165-76 - PubMed
- Adv Drug Deliv Rev. 2002 Jun 17;54(4):477-85 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources